Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio in aperto che confronta il lutezio (177Lu) Vipivotide Tetraxetan rispetto all'osservazione nell'OMPC positivo per PSMA. (PSMA-DC)

20 ottobre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio internazionale, prospettico, in aperto, multicentrico, randomizzato di fase III che confronta lutezio (177Lu) vipivotide tetraxetano (AAA617) rispetto all'osservazione per ritardare la castrazione o la recidiva della malattia in pazienti maschi adulti con antigene prostatico specifico di membrana (PSMA) oligometastatico positivo Cancro alla prostata (OMPC)

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

All participants will be assessed for eligibility and will undergo baseline disease assessments including a mandatory gallium (68Ga) gozetotide (also known as [68Ga]Ga-PSMA-11) or piflufolastat (18F) ( also known as[18F]DCFPyL) PET/CT scan and CI (i.e., CT/MRI and bone scans).

Piflufolastat (18F) PET/CT scan will be performed in countries where it is approved.

Stereotactic Body Radiation Therapy (SBRT) will be administered to all metastatic Prostate Cancer (PC) lesions after randomization and before the start of treatment with AAA617 or observation.

  • The duration of SBRT procedures is approximately 3 weeks.
  • For participants randomized to the investigational arm (AAA617), the treatment duration will be up to 4 cycles of AAA617. For participants randomized to the control arm (observation) the treatment duration will end at the last fraction of SBRT administration.
  • The visit frequency will be every week 1 and 3 of each of the 4 cycles and every 16 weeks thereafter (for both arms) until first event of disease progression (RECIST 1.1)
  • The study duration is approximately 7.5 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

450

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • CABA, Argentina, C1181ACH
        • Reclutamento
        • Novartis Investigative Site
      • Caba, Argentina, C1431FWO
        • Reclutamento
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1426ANZ
        • Reclutamento
        • Novartis Investigative Site
    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • Reclutamento
        • Novartis Investigative Site
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Reclutamento
        • Novartis Investigative Site
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Reclutamento
        • Novartis Investigative Site
    • Victoria
      • Malvern, Victoria, Australia, 3144
        • Reclutamento
        • Novartis Investigative Site
      • Linz, Austria, 4020
        • Reclutamento
        • Novartis Investigative Site
      • Vienna, Austria, 1090
        • Reclutamento
        • Novartis Investigative Site
      • Aalst, Belgio, 9300
        • Reclutamento
        • Novartis Investigative Site
      • Ghent, Belgio, 9000
        • Reclutamento
        • Novartis Investigative Site
      • Wilrijk, Belgio, 2610
        • Reclutamento
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasile, 01246-000
        • Reclutamento
        • Novartis Investigative Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Reclutamento
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Reclutamento
        • Novartis Investigative Site
    • Ontario
      • London, Ontario, Canada, N6A 4G5
        • Reclutamento
        • Novartis Investigative Site
      • Ottawa, Ontario, Canada, K1H 8L6
        • Reclutamento
        • Novartis Investigative Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Reclutamento
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H2X 1R9
        • Reclutamento
        • Novartis Investigative Site
      • Québec, Quebec, Canada, G1J 1Z4
        • Reclutamento
        • Novartis Investigative Site
      • Olomouc, Cechia, 779 00
        • Reclutamento
        • Novartis Investigative Site
      • Prague, Cechia, 150 06
        • Reclutamento
        • Novartis Investigative Site
    • Poruba
      • Ostrava, Poruba, Cechia, 708 52
        • Reclutamento
        • Novartis Investigative Site
      • Beijing, Cina, 100036
        • Reclutamento
        • Novartis Investigative Site
      • Guangzhou, Cina, 510060
        • Reclutamento
        • Novartis Investigative Site
      • Shanghai, Cina, 200001
        • Reclutamento
        • Novartis Investigative Site
      • Bogotá, Colombia, 110131
        • Reclutamento
        • Novartis Investigative Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 110111
        • Reclutamento
        • Novartis Investigative Site
      • Bordeaux, Francia, 33076
        • Reclutamento
        • Novartis Investigative Site
      • Bron, Francia, 69677
        • Reclutamento
        • Novartis Investigative Site
      • Clermont-Ferrand, Francia, 63011
        • Reclutamento
        • Novartis Investigative Site
      • Rouen, Francia, 76038
        • Reclutamento
        • Novartis Investigative Site
      • Saint-Herblain, Francia, 44805
        • Reclutamento
        • Novartis Investigative Site
    • Hauts De Seine
      • Saint-Cloud, Hauts De Seine, Francia, 92210
        • Reclutamento
        • Novartis Investigative Site
      • Aachen, Germania, 52074
        • Reclutamento
        • Novartis Investigative Site
      • Augsburg, Germania, 86179
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 10249
        • Reclutamento
        • Novartis Investigative Site
      • Essen, Germania, 45147
        • Reclutamento
        • Novartis Investigative Site
      • Münster, Germania, 48149
        • Reclutamento
        • Novartis Investigative Site
      • Rostock, Germania, 18057
        • Reclutamento
        • Novartis Investigative Site
    • Bavaria
      • Munich, Bavaria, Germania, 81377
        • Reclutamento
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germania, 50937
        • Reclutamento
        • Novartis Investigative Site
      • Fukuoka, Giappone, 8128582
        • Reclutamento
        • Novartis Investigative Site
      • Fukuoka, Giappone, 8110213
        • Reclutamento
        • Novartis Investigative Site
      • Fukuoka, Giappone, 8120033
        • Reclutamento
        • Novartis Investigative Site
      • Fukushima, Giappone, 9601295
        • Reclutamento
        • Novartis Investigative Site
      • Ishikawa, Giappone, 9208641
        • Reclutamento
        • Novartis Investigative Site
      • Kyoto, Giappone, 6068507
        • Reclutamento
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Giappone, 2778577
        • Reclutamento
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Giappone, 0608648
        • Reclutamento
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Giappone, 6500047
        • Reclutamento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Giappone, 2360004
        • Reclutamento
        • Novartis Investigative Site
    • Tokyo
      • Chuo Ku, Tokyo, Giappone, 1040045
        • Reclutamento
        • Novartis Investigative Site
      • Athens, Grecia, 115 28
        • Reclutamento
        • Novartis Investigative Site
      • Thessaloniki, Grecia, 540 07
        • Reclutamento
        • Novartis Investigative Site
      • Beersheba, Israele, 8457108
        • Reclutamento
        • Novartis Investigative Site
      • Haifa, Israele, 3109601
        • Reclutamento
        • Novartis Investigative Site
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Novartis Investigative Site
      • Petah Tikva, Israele, 4941492
        • Reclutamento
        • Novartis Investigative Site
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Novartis Investigative Site
    • BS
      • Brescia, BS, Italia, 25123
        • Ritirato
        • Novartis Investigative Site
    • FE
      • Cona, FE, Italia, 44124
        • Reclutamento
        • Novartis Investigative Site
    • GE
      • Genova, GE, Italia, 16132
        • Reclutamento
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20141
        • Reclutamento
        • Novartis Investigative Site
      • Rozzano, MI, Italia, 20089
        • Reclutamento
        • Novartis Investigative Site
    • PI
      • Pisa, PI, Italia, 56126
        • Reclutamento
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italia, 00168
        • Reclutamento
        • Novartis Investigative Site
    • VR
      • Negrar, VR, Italia, 37024
        • Reclutamento
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 59100
        • Reclutamento
        • Novartis Investigative Site
    • Selangor
      • Petaling Jaya, Selangor, Malaysia, 46050
        • Reclutamento
        • Novartis Investigative Site
      • Huxquilucan, Messico, 52763
        • Reclutamento
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Messico, 14050
        • Reclutamento
        • Novartis Investigative Site
      • Amsterdam, Olanda, 1066 CX
        • Reclutamento
        • Novartis Investigative Site
      • San Juan, Porto Rico, 00921
        • Reclutamento
        • VA Caribbean Healthcare System
        • Investigatore principale:
          • Bartolo Santiago-Delgado
        • Contatto:
      • Coventry, Regno Unito, CV2 2DX
        • Reclutamento
        • Novartis Investigative Site
      • London, Regno Unito, SW3 6JJ
        • Reclutamento
        • Novartis Investigative Site
      • London, Regno Unito, NW3 2QG
        • Reclutamento
        • Novartis Investigative Site
    • Avon
      • Bristol, Avon, Regno Unito, BS2 8ED
        • Reclutamento
        • Novartis Investigative Site
    • Surrey
      • Guildford, Surrey, Regno Unito, GU2 7XX
        • Reclutamento
        • Novartis Investigative Site
      • Singapore, Singapore, 119074
        • Reclutamento
        • Novartis Investigative Site
      • Singapore, Singapore, 168583
        • Reclutamento
        • Novartis Investigative Site
      • Bratislava, Slovacchia, 833 10
        • Reclutamento
        • Novartis Investigative Site
      • Košice, Slovacchia, 041 91
        • Reclutamento
        • Novartis Investigative Site
      • Nitra, Slovacchia, 949 01
        • Reclutamento
        • Novartis Investigative Site
      • Trenčín, Slovacchia, 911 01
        • Reclutamento
        • Novartis Investigative Site
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Novartis Investigative Site
      • Madrid, Spagna, 28041
        • Reclutamento
        • Novartis Investigative Site
      • Madrid, Spagna, 28040
        • Reclutamento
        • Novartis Investigative Site
      • Seville, Spagna, 41013
        • Reclutamento
        • Novartis Investigative Site
      • Valencia, Spagna, 46010
        • Reclutamento
        • Novartis Investigative Site
    • Andalusia
      • Granada, Andalusia, Spagna, 18014
        • Reclutamento
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 08907
        • Reclutamento
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spagna, 08025
        • Reclutamento
        • Novartis Investigative Site
    • Murcia
      • El Palmar, Murcia, Spagna, 30120
        • Reclutamento
        • Novartis Investigative Site
    • Arkansas
      • Fayetteville, Arkansas, Stati Uniti, 72703
        • Reclutamento
        • Highlands Oncology Group
        • Investigatore principale:
          • Joseph Thaddeus Beck
        • Contatto:
    • California
      • Los Angeles, California, Stati Uniti, 90073
        • Reclutamento
        • VA Greater LA Healthcare System
        • Investigatore principale:
          • Matthew Rettig
        • Contatto:
      • Palo Alto, California, Stati Uniti, 94304-1207
        • Reclutamento
        • VA Palo Alto Health Care System
        • Investigatore principale:
          • Minal Vasanawala
        • Contatto:
      • Palo Alto, California, Stati Uniti, 94304
        • Reclutamento
        • Stanford University
        • Investigatore principale:
          • Hilary Bagshaw
        • Contatto:
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • UCSF
        • Investigatore principale:
          • Steven Seyedin
        • Contatto:
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Rocky Mountain Cancer Centers
        • Investigatore principale:
          • Allen Cohn
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32256
        • Reclutamento
        • Cancer Specialists of North Florida
        • Investigatore principale:
          • Richard Cassidy
        • Contatto:
      • Pensacola, Florida, Stati Uniti, 32503
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30318
        • Reclutamento
        • Piedmont Healthcare
        • Contatto:
          • Sharon Joseph
        • Investigatore principale:
          • Adam Nowlan
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago
        • Investigatore principale:
          • Mohammad Atiq
        • Contatto:
      • Elk Grove, Illinois, Stati Uniti, 60007
    • Iowa
      • Des Moines, Iowa, Stati Uniti, 50323
        • Reclutamento
        • Unity Point Clinic
        • Contatto:
        • Investigatore principale:
          • Mark Kellerman
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • University of Kansas Hospital
        • Investigatore principale:
          • Xinglei Shen
        • Contatto:
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70809
        • Reclutamento
        • Mary Bird Perkins Cancer Center
        • Investigatore principale:
          • Victor Lin
        • Contatto:
      • Metairie, Louisiana, Stati Uniti, 70006
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21231
        • Reclutamento
        • Johns Hopkins Kimmel Com Cancer Ctr
        • Investigatore principale:
          • Ana Kiess
        • Contatto:
      • Baltimore, Maryland, Stati Uniti, 21201
        • Reclutamento
        • University of Maryland Medical Ctr
        • Investigatore principale:
          • Arif Hussain
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Reclutamento
        • Dana Farber Cancer Institute
        • Investigatore principale:
          • Mai Anh Huynh
        • Contatto:
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Beth Israel Deaconess Med Ctr
        • Investigatore principale:
          • David J Einstein
        • Contatto:
    • Michigan
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Ritirato
        • BAMF Health
      • Royal Oak, Michigan, Stati Uniti, 48073
        • Reclutamento
        • William Beaumont Hospital
        • Investigatore principale:
          • Andrew Thompson
        • Contatto:
      • Royal Oak, Michigan, Stati Uniti, 48073
        • Ritirato
        • Profound Research LLC
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic Rochester
        • Investigatore principale:
          • Ryan Phillips
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Wash U School of Medicine
        • Investigatore principale:
          • Hiram Gay
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63104
      • St Louis, Missouri, Stati Uniti, 63106
        • Ritirato
        • VA St Louis Health Care System
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
        • Reclutamento
        • The Urology Center PC DBA UroHealth Partners
        • Investigatore principale:
          • Andrew Trainer
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Ctr
        • Investigatore principale:
          • Daniel Gorovets
        • Contatto:
      • Syracuse, New York, Stati Uniti, 13210
        • Reclutamento
        • Associated Med Professionals of NY
        • Investigatore principale:
          • Steven Finkelstein
        • Contatto:
      • The Bronx, New York, Stati Uniti, 10467-2490
        • Reclutamento
        • Montefiore Hospital
        • Investigatore principale:
          • Benjamin A Gartrell
        • Contatto:
    • North Carolina
      • Greenville, North Carolina, Stati Uniti, 27858
        • Reclutamento
        • East Carolina University
        • Investigatore principale:
          • Andrew Ju
        • Contatto:
    • Ohio
      • Kettering, Ohio, Stati Uniti, 45409
        • Reclutamento
        • Dayton Physicians
        • Investigatore principale:
          • Trevor Bluemel
        • Contatto:
    • Oregon
      • Springfield, Oregon, Stati Uniti, 97477
        • Reclutamento
        • Oregon Urology Institute
        • Investigatore principale:
          • Bryan Mehlhaff
        • Contatto:
    • South Carolina
      • Myrtle Beach, South Carolina, Stati Uniti, 29572
        • Reclutamento
        • Carolina Urologic Research Center
        • Investigatore principale:
          • Neal D Shore
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University Medical Center
        • Investigatore principale:
          • Kerry Schaffer
        • Contatto:
    • Texas
      • Dallas, Texas, Stati Uniti, 75390-9034
        • Reclutamento
        • Univ of Texas Southwest Med Center
        • Investigatore principale:
          • Kevin Courtney
        • Contatto:
      • El Paso, Texas, Stati Uniti, 79912
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23502
        • Reclutamento
        • Virginia Oncology Associates
        • Investigatore principale:
          • Mark Fleming
        • Contatto:
      • Wytheville, Virginia, Stati Uniti, 24382
        • Reclutamento
        • Blue Ridge Cancer Center
        • Investigatore principale:
          • David Buck
        • Contatto:
      • Geneva, Svizzera, 1211
        • Reclutamento
        • Novartis Investigative Site
      • Lucerne, Svizzera, 6006
        • Completato
        • Novartis Investigative Site
      • Zurich, Svizzera, 8063
        • Reclutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Reclutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Reclutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 103616
        • Reclutamento
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Reclutamento
        • Novartis Investigative Site
      • Budapest, Ungheria, 1122
        • Reclutamento
        • Novartis Investigative Site
      • Budapest, Ungheria, 1083
        • Reclutamento
        • Novartis Investigative Site
    • Hajdu Bihar Megye
      • Debrecen, Hajdu Bihar Megye, Ungheria, 4032
        • Reclutamento
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Key Inclusion criteria:

  1. Histologically confirmed prostate cancer prior to randomization

  2. Participants must have biochemically recurrent disease after definitive treatment to prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to prostate bed/pelvic nodes)) or External beam Radiation Therapy (EBRT), (prostate alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy prior to randomization. Biochemical recurrence (BCR) is defined as: nadir PSA + 2 ng/mL post XRT (if participant received-radiation therapy to intact prostate) and PSA > 0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT))

  3. Participants must have OMPC with 1-5 PSMA -positive metastatic lesions on screening PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as visually assessed by BIRC. For definition of PSMA PET positivity, please refer to Section 8.1 and the Imaging Manual. Metastatic lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a), bone (M1b), lung and others visceral (M1c) except liver and brain classified using American Joint Committee on Cancer (AJCC) 8. When counting the number of oligometastatic lesions, each lesion is counted as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and one extra-pelvic lymph node will be counted as two metastatic lesions)

  4. At least 1 PSMA-positive lesion must be a distant metastasis (M1) per AJCC8 classification at screening. For AJCC M staging, PSMA PET/CT information should be used

  5. Participants must have a negative CI for M1 disease at screening.

    Note:

    • For a participant not to be eligible, CI positive M1 lesions should be unequivocal in CI scans, i.e., potentially not attributable to findings thought to represent something other than tumor (e.g., degenerative, or post-traumatic changes or Paget's disease in bone lesions). For CI assessments, bone lesions must be assessed by bone scan only and soft tissue lesions must be assessed by CT/MRI scans only at screening.
    • Prior knowledge of PSMA PET positivity should not influence the radiologist (reader) in determination of CI positivity. Two different readers will be involved, one reader for PSMA PET/CT scan and one reader for CI: Reader will be blinded to PSMA PET scan results while reading CI scans. Reader should not modify their assessment of CI scans (e.g. changing a lesion previously identified as equivocal in CI to unequivocal) after reading the PSMA PET scan. Similarly, biopsy positivity should not influence the reader in the assessment of CI positivity. More details on the reading paradigm will be provided in the imaging charter
    • MRI for radiation treatment planning may show M1 disease but this will not exclude the participant from the study if the lesion is deemed negative per baseline CT or bone scans
    • Participants with pelvic disease (N1) seen in CI are allowed if the local spread is below common iliac bifurcation (per AJCC 8 definition of local disease)
    • Distant lymph node disease (M1a) that is visible per CI and less than 10mm in the short axis is not exclusionary irrespective of PSMA PET positivity.
    • If a previously surgically removed lesion was unequivocal for M1 by bone scan or CT, the participant is not eligible.
  6. All metastatic lesions detected at screening must be amenable to SBRT

  7. Non-castration testosterone level >100 ng/dL at screening

Key Exclusion criteria:

  1. Participants with de novo OMPC at screening

  2. Unmanageable concurrent bladder outflow obstruction or urinary incontinence at screening. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed

  3. Prior therapy with:

    1. ADT (including bilateral orchiectomy) and ARPIs used for metastatic prostate cancer treatment

      • Participants who received AR-directed therapy, whether ADT or an ARPI or both, as neoadjuvant or adjuvant therapy as a component of their primary therapy, are eligible provided that they discontinued therapy ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. ARPI's as a term includes both contemporary androgen synthesis inhibitors (e.g., abiraterone, galeterone, and orteneronel), and receptor inhibitors (enzalutamide, apalutamide and darolutamide).

      • Patients who biochemically relapsed after primary therapy may also have had treatment with AR directed therapy and participants who had SBRT with ADT are also eligible provided that the ARPI +/- ADT or ADT alone was terminated

        ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy.

      • Participants who received first generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) for biochemical recurrence or adjuvant/neoadjuvant therapy are eligible provided that they discontinued therapy ≥3 months prior to randomization.

      • Participants who have discontinued ADT due to disease progression are not eligible (i.e., Castration-Resistant Prostate Cancer (CRPC) participants)

    2. Other hormonal therapy. e.g.,

      •Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) if used in the context of prostate cancer treatment. Same medications are allowed if used for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if stopped ≥3 months before randomization.

    3. Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand therapy)

    4. Immunotherapy (e.g., sipuleucel-T)

    5. Chemotherapy, except if administered in the adjuvant/neoadjuvant setting completed > 12 months before randomization

    6. Any other investigational or systemic agents for metastatic disease

  4. Radiation therapy external beam radiation therapy (EBRT) and brachytherapy within 28 days before randomization

  5. Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal therapy (see ADT initiation guidance in Section 6.8.2), Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor, biological therapy or investigational therapy

  6. Diagnosed at screening with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease/treatment free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer.

  7. History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as:

    • Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second or third degree Atrioventricular (AV) block without a pacemaker
    • History of familial long QT syndrome or known family history of Torsades de Pointe
  8. Participants in immediate need of ADT or other systemic therapy as assessed by the investigator. In addition, investigators should only enroll participants who are committed to delay castration in accordance with the scope of the study and are willing to wait to start systemic therapy until distant progression (MFS event) as assessed by CI (consisting with existing treatment guidelines) and confirmed by BIRC is reached. This must be discussed with the participants before ICF is signed.

Other protocol defined Inclusion/Exclusion may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)

All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.

Radiopharmaceutical solution for infusion/injection

Altri nomi:
  • (177Lu) vipivotide tetraxetano

Provided as ready-to-use radiopharmaceutical

Provided as PSMA-11 Kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide

Nessun intervento: Control arm: observation (watchful waiting)

All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)
Lasso di tempo: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months

Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS) is defined as the time from randomization to first evidence of radiographically detectable bone or soft tissue distant metastasis by conventional imaging (i.e., Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) and bone scans) as assessed by BIRC using RECIST 1.1 or death due to any cause, whichever occurs first.

Participants who are alive without distant metastasis at the analysis data cut-off or are lost to follow-up at the time of analysis will be censored for MFS at the time of their last adequate radiographic assessment. Clinical deterioration without objective radiographic evidence will not be considered as documented distant metastasis.

From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Key secondary endpoint: Time to Hormonal Therapy (TTHT)
Lasso di tempo: From date of randomization until date of Androgen Deprivation Therapy (ADT), assessed up to approximately 74 months

Time to Hormonal Therapy (TTHT) is defined as the time from randomization to the time to Androgen Deprivation Therapy (ADT). The type of hormonal therapy will be at the discretion of the Investigator.

From date of randomization until date of Androgen Deprivation Therapy (ADT), assessed up to approximately 74 months
Investigator assessed Metastasis Free Survival (MFS)
Lasso di tempo: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death from any cause, whichever occurs first, assessed up to approximately 74 months

Investigator assessed Metastasis Free Survival (MFS) is defined as the time from randomization to the first evidence of radiographically detectable bone or soft tissue distant metastasis by conventional imaging (i.e., CT/MRI and bone scans) as assessed by Investigator using RECIST 1.1 or death from any cause, whichever occurs first.

From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death from any cause, whichever occurs first, assessed up to approximately 74 months
Time to prostate specific antigen (PSA) progression (TTPSAP)
Lasso di tempo: From date of randomization until date of first PSA progression, assessed up to approximately 74 months

Time to prostate specific antigen (PSA) progression (TTPSAP) is defined as time from randomization to first PSA progression 1. First PSA progression 1 is defined as a rising PSA confirmed on repeated measurement at least 3 weeks later, and at least greater than 25% and >= 2 ng/mL above nadir or baseline, whichever is lower. In the absence of PSA progression, TTPSAP will be censored at the last PSA measurement.

From date of randomization until date of first PSA progression, assessed up to approximately 74 months
Radiographic Progression Free Survival (rPFS)
Lasso di tempo: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 74 months

Radiographic progression free survival (rPFS) is defined as the time from randomization to first documentation of confirmed radiographic progressive disease or death due to any cause (whichever occurs first) by conventional imaging (i.e., CT/MRI and bone scans) using RECIST 1.1. The rPFS will be analyzed based on BIRC and Investigator assessments respectively.

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 74 months
Time to next therapy (local or systemic)
Lasso di tempo: From date of randomization until initiation of the next line of therapy (local or systemic), assessed up to approximately 74 months

Time to next therapy (local or systemic) is defined as the time from randomization to initiation of the next line of therapy (local or systemic). Next-line therapy is defined as the first new (local or systemic) anti-neoplastic therapy initiated after discontinuation of study treatment regardless of end of treatment (EOT) reason.

From date of randomization until initiation of the next line of therapy (local or systemic), assessed up to approximately 74 months
24-month prostate-specific antigen (PSA) progression free survival (PFS)
Lasso di tempo: From date of randomization until date of first documented PSA progression 2 or death from any cause, whichever occurs first, assessed up to approximately 74 months

24-month PSA PFS is defined as PSA PFS at 24 months. PSA PFS is defined as the time from date of randomization to the date of first documented PSA progression 2 or death from any cause, whichever occurs first. PSA progression 2 is defined as a PSA concentration above the nadir (or baseline if lower) of >= 0.5 ng/mL, confirmed by repeated measurement at least 3 weeks later. PSA PFS will be censored if no PSA PFS event is observed before the first to occur analysis cut-off date. The censoring date will be the date of the last adequate tumor assessment prior to cut-off.

From date of randomization until date of first documented PSA progression 2 or death from any cause, whichever occurs first, assessed up to approximately 74 months
Time to symptomatic progression
Lasso di tempo: From date of randomization until date of first documented symptomatic progression, assessed up to approximately 74 months

Time to symptomatic progression is defined as time from randomization to the date of first documented event for any of the following, whichever occurs first: development of symptomatic skeletal event, escalation in cancer-related pain or worsening of disease-related symptoms leading to the initiation of a new systemic anticancer therapy, development of clinically significant symptoms due to local or regional tumor progression leading to surgery or radiation therapy.

From date of randomization until date of first documented symptomatic progression, assessed up to approximately 74 months
Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
Lasso di tempo: From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACTGeneral (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months
Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT) Questionnaire
Lasso di tempo: From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months

The FACT-RNT (Functional Assessment of Cancer Therapy - Radionuclide Therapy) is a Patient Reported Outcomes (PRO) new measure developed using FACIT specific questions (items), selected from FACIT item bank, to assess treatment-related symptoms of special interest associated with radioligand therapies.

The FACT-RNT contains items assessing dry mouth, dry eyes, vomiting, diarrhea, constipation, loss of appetite, fatigue, impact of fatigue, bone pain, and isolation due to illness or treatment. FACT-RNT score range 0 to 60, with higher score indicating better quality of life.

From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months
Brief Pain Inventory - Short Form (BPI-SF) Questionnaire
Lasso di tempo: From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months

The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item selfreport questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months
European Quality of Life (EuroQol) - 5 Domain 5 Level scale (EQ-5D- 5L)
Lasso di tempo: From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months

EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.

From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months
Time to First Symptomatic Skeletal Event (TTSE)
Lasso di tempo: From date of randomization till end of treatment (EOT) or death, whichever happens first, assessed up to approximately 74 months

Time to first symptomatic skeletal event (TTSSE) is defined as date of randomization to the date of first new SSE or death from any cause, whichever occurs first. Symptomatic skeletal events (SSE) will be defined by the occurrence of any of the following (whichever occurs earlier): symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain.

From date of randomization till end of treatment (EOT) or death, whichever happens first, assessed up to approximately 74 months
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Lasso di tempo: From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months

The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months
Dose modifications and intensity for AAA617
Lasso di tempo: From date of randomization until end of treatment (EOT), assessed up to approximately 30 months

Dose modifications (dose interruptions and reductions) and dose intensity for AAA617 will be assessed and summarized using descriptive statistics.

From date of randomization until end of treatment (EOT), assessed up to approximately 30 months
Overall survival (OS)
Lasso di tempo: From date of randomization until date of death from any cause, assessed up to approximately 74 months

Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. OS time for participants who are alive at the end of the study or are lost to follow-up will be censored at the date of last contact.

From date of randomization until date of death from any cause, assessed up to approximately 74 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 marzo 2024

Completamento primario (Stimato)

25 aprile 2028

Completamento dello studio (Stimato)

3 ottobre 2031

Date di iscrizione allo studio

Primo inviato

3 luglio 2023

Primo inviato che soddisfa i criteri di controllo qualità

3 luglio 2023

Primo Inserito (Effettivo)

11 luglio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CAAA617D12302
  • 2022-502956-29-00 (Altro identificatore: EU CT number)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .